Cargando…

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas

Background: Malignant gliomas are heterogeneous brain tumors with the potential for aggressive disease progression, as influenced by suppressive immunoediting. Given the success and enhanced potential of immune-checkpoint inhibitors in immunotherapy, we focused on the connections between genetic alt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mu, Luyan, Long, Yu, Yang, Changlin, Jin, Linchun, Tao, Haipeng, Ge, Haitao, Chang, Yifan E., Karachi, Aida, Kubilis, Paul S., De Leon, Gabriel, Qi, Jiping, Sayour, Elias J., Mitchell, Duane A., Lin, Zhiguo, Huang, Jianping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882817/ https://www.ncbi.nlm.nih.gov/pubmed/29643764 http://dx.doi.org/10.3389/fnmol.2018.00082

Ejemplares similares

The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
por: Wang, Tian-Xiang, et al.
Publicado: (2019)

The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo
por: Suijker, Johnny, et al.
Publicado: (2015)

Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells
por: Hujber, Zoltán, et al.
Publicado: (2017)

CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression
por: Mu, Luyan, et al.
Publicado: (2017)

Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate
por: Fan, Jing, et al.
Publicado: (2014)

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
por: Carbonneau, Mélissa, et al.
Publicado: (2016)

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
por: Li, Luyuan, et al.
Publicado: (2015)

The Enzymology of 2-Hydroxyglutarate, 2-Hydroxyglutaramate and 2-Hydroxysuccinamate and Their Relationship to Oncometabolites
por: Hariharan, Vivek A., et al.
Publicado: (2017)

Optimizing T Cell-Based Therapy for Glioblastoma
por: Karachi, Aida, et al.
Publicado: (2021)

Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer
por: Shim, Eun-Hee, et al.
Publicado: (2015)

Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite
por: Berger, Raffaela S., et al.
Publicado: (2021)

Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate and promotes histone methylation
por: Fan, Jing, et al.
Publicado: (2014)

The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms
por: Rakheja, Dinesh, et al.
Publicado: (2013)

Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases
por: Evans, Brad, et al.
Publicado: (2015)

Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors
por: Thomas, Teena, et al.
Publicado: (2023)

Oncometabolite D-2-hydroxyglutarate—dependent metabolic reprogramming induces skeletal muscle atrophy during cancer cachexia
por: Zhu, Xinting, et al.
Publicado: (2023)

The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation
por: Liu, Lizhen, et al.
Publicado: (2021)

Accumulation of oncometabolite D-2-Hydroxyglutarate by SLC25A1 inhibition: A metabolic strategy for induction of HR-ness and radiosensitivity
por: Xiang, Kexu, et al.
Publicado: (2022)

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients
por: Choi, Changho, et al.
Publicado: (2012)

Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2023)

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner
por: Viswanath, Pavithra, et al.
Publicado: (2018)

Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis
por: Pickard, Amanda J., et al.
Publicado: (2016)

Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity
por: Chittaranjan, Suganthi, et al.
Publicado: (2014)

Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas
por: Leather, Thomas, et al.
Publicado: (2017)

(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas
por: Richardson, Leland G., et al.
Publicado: (2019)

Oncometabolite D-2-Hydroxyglutarate enhances gene silencing through inhibition of specific H3K36 histone demethylases
por: Janke, Ryan, et al.
Publicado: (2017)

Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma
por: Nakagawa, Makoto, et al.
Publicado: (2022)

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate
por: Andronesi, Ovidiu C., et al.
Publicado: (2018)

Metabolomic analysis identifies differentially produced oral metabolites, including the oncometabolite 2-hydroxyglutarate, in patients with head and neck squamous cell carcinoma
por: Mukherjee, Pranab K., et al.
Publicado: (2016)

The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells
por: Chen, Jing-Yi, et al.
Publicado: (2016)

D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice
por: Akbay, Esra A., et al.
Publicado: (2014)

SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma
por: Chan, Ti-Chun, et al.
Publicado: (2020)

A Drosophila model of combined D-2- and L-2-hydroxyglutaric aciduria reveals a mechanism linking mitochondrial citrate export with oncometabolite accumulation
por: Li, Hongde, et al.
Publicado: (2018)

Renal oncometabolite L-2-hydroxyglutarate imposes a block in kidney tubulogenesis: Evidence for an epigenetic basis for the L-2HG-induced impairment of differentiation
por: Taub, Mary, et al.
Publicado: (2022)

DDRE-27. IDH MUTATED GLIOMAS PROMOTE EPILEPTOGENESIS VIA D-2-HYDROXYGLUTARATE DEPENDENT MTOR HYPERACTIVATION
por: Mortazavi, Armin, et al.
Publicado: (2021)

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
por: Jin, Linchun, et al.
Publicado: (2019)

Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
por: Fiehn, Oliver, et al.
Publicado: (2016)

Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
por: Showalter, Megan Reed, et al.
Publicado: (2017)

Oncometabolites and the response to radiotherapy
por: Xiang, Kexu, et al.
Publicado: (2020)

Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production
por: Kotredes, Kevin P., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r40p1turekv50980gqb5d9jqgj